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Summary
Replication of the human immunodeficiency virus (HIV) necessitates the two viral enzymes
reverse transcriptase (RT) and integrase (IN). These two proteins are found to associate in a
large nucleoprotein complex called the preintegration complex (PIC) together with viral
nucleic acids and other viral and host proteins. Since the two proteins are localised together in
the host cell, a direct interaction between them can exist, although it has been difficult to
demonstrate such interaction. In this study, RT and IN were produced by in vitro transcription
and translation and the proteins were used to study possible RT-IN interactions by ELISA.
The RT and IN coding regions were amplified by PCR from a full length HIV-1 HxB2 clone
and ligated in-frame into the in vitro translation vector pCITE-5b(+). The two plasmids
generated, pCITE-RT and pCITE-IN were constructed and verified by sequencing and
restriction enzyme analysis.
A coupled in vitro transcription and translation kit based on rabbit reticulocyte lysate was
utilised together with the two plasmids in order to obtain RT and IN. The proteins were
produced unmarked since marked amino acids possibly could obscure an eventual interaction.
Verification of the protein products was done by Western blotting having specific monoclonal
antibodies. The proteins produced were not purified from the reticulocyte lysate but used
directly in an ELISA-format to try to detect any interactions between RT and IN.
With the ELISA-format, no interactions could be demonstrated. The signal was the same for
all dilutions of the coating protein, as well as for the negative control. The most likely
explanation for this is that there are some proteins in the reticulocyte lysate that interacts with
both RT and IN.
If in vitro translated proteins are going to be used to investigate protein-protein interactions by
this ELISA method they need to be purified first. An other possibility is to cotranslate the two
proteins in vitro. It is not sure that an eventual direct interaction between RT and IN can be
detected by ELISA. Other components of the PIC may need to be present for a direct
interaction to occur.
Introduction
1
1 Introduction
The human immunodeficiency virus type 1 (HIV-1) is the causative agent of acquired
immunodeficiency syndrome (AIDS). HIV-1 is a retrovirus of the lentivirus subfamily.
1.1 Genomic organisation of HIV-1
The genome of HIV-1 consists of two identical single-stranded RNA molecules which is
converted to double stranded DNA by the viral enzyme reverse transcriptase (RT). Long
terminal repeats (LTRs) are flanking the viral genes on the double-stranded DNA. The HIV-1
genome has three major coding regions; gag, pol and env. The gag gene encodes the virion
capsid proteins, the pol gene encodes the viral enzymes needed for replication (protease (PR),
integrase (IN) and RT) and the env gene encodes the envelope glycoprotein. In addition to the
gag, pol and env coding regions, the HIV-1 encodes several other proteins. This includes Vif
and Vpr that are part of the viral particle, Tat and Rev that regulates viral gene expression and
Vpu and Nef that interacts with the cellular machinery to promote virus propagation [1]. An
overview of the viral genome and virion structure is given in Figure 1.
The virion has a spherical shape and is about 110 nm in diameter. It consists of a lipid
bilayer envelope that surrounds the cone-shaped nucleocapsid. Computer simulations and
scanning electron microscopy has shown that the virion is icosahedral [2, 3], lthough the
overall shape of the virion is spherical. The nucleocapsid consists of the viral RNA molecules
surrounded by the Gag proteins; MA which is located between the lipid envelope and the
nucleocapsid, CA which forms the capsid shell and NC which binds to the RNA. A tRNALys3
primer is located inside the nucleocapsid, together with the viral enzymes PR, RT and IN. The
viral accessory proteins Vif and Vpr are also present in the viral particle, but their exact
location is still unknown.
The viral envelope contains a number of knobs that shows triangular symmetry [4]. A
knob is thought to consist of four heterodimers of the Env gp, each heterodimer is composed
of a surface subunit (SU, gp120) and a transmembrane subunit (TM, gp41).
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Figure 1. The HIV-1 virion structure.  The precursor polyproteins Gag, Pol, and Env are enzymatically
cleaved to yield the mature virion proteins. The Gag and Pol polyproteins are cleaved by the viral protease (PR)
to produce the following proteins; the matrix protein (MA), the major capsid protein (CA), the nucleocapsid
protein (NC), protease (PR), reverse transcriptase (RT) and integrase (IN). The Env polyprotein is cleaved by a
cellular protease to give the surface subunit (SU) gp 120 and the transmembrane subunit (TM) gp 41 of the
surface Env glycoprotein. The HIV-1 genome also has open reading frames for the regulatory proteins Tat and
Rev, and the accessory proteins Vif, Vpr, Vpu and Nef.
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Biochemical and immunochemical analyses have also shown that the HIV membrane contains
several cellular proteins acquired during budding [5]. Their role in viral replication has not
been resolved.
1.2 The HIV-1 lifecycle
In order to simplify the rather complex lifecycle of HIV-1, a schematic overview is presented
in Figure 2. A more detailed description of each step is given in the chapters below.
1.2.1 Binding and entry
The HIV-1 virus has the CD4 molecule as its major receptor. Entry of HIV-1 into target cells
starts with an interaction between gp120, CD4 and a seven-transmembrane G protein coupled
chemokine coreceptor [6]. Binding of gp 120 to CD4 induces conformational changes and
increases the exposure of gp41 epitopes allowing the host cellular membrane to fuse with the
lipid-envelope coat of the virion [7-9]. Following fusion, the virion core is released into the
cytoplasm of the host cell (Figure 2).
At this stage, the viral RNA is a part of a large nucleoprotein complex in which the
reverse transcription occurs. This complex contains at least RT, IN and a portion of the MA
protein [10-13] and is also known as the preintegration complex (PIC). See 1.3 for details.
1.2.2 Reverse transcription
Reverse transcription of the viral RNA starts from a tRNALys3 primer bound to a primer
binding site (PBS) at the viral RNA. The enzyme reverse transcriptase (RT) copies the 5’ R-
U5 (repeat-unique 5’) region of the RNA into “minus strand strong stop” DNA and the RNase
H activity of RT degrades the RNA. This degradation induces the first strand transfer, where
the newly synthesised DNA hybridises to the complementary 3’ R (repeat) region of either the
same RNA strand or on the other copy of viral DNA. Then the minus strand DNA synthesis
continues through the viral genome. Again RNase H degrades the RNA in the RNA-DNA
hybrid, but leaves a 16-base polypurine tract (PPT) 5’ to the U3 (unique 3’) region. This PPT
is used to prime the synthesis of the plus strand DNA. When the synthesis reaches the
tRNALys3 primer, it stops and the primer is removed by RNase H. Then the second strand
transfer reaction occurs and the newly synthesised PBS at the plus strand hybridises with the
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complementary PBS on the minus strand. Finally RT completes the synthesis of both the
strands.
1.2.3 Nuclear transport and integration
The double stranded DNA remains attached to the nucleoprotein complex, from this stage
called the preintegration complex (PIC). A detailed description of this complex will be given
later (see 1.3.1). This complex is transported to the cell nucleus where the integration occurs.
For details see 1.3.2.
After the DNA has reached the nucleus, integrase (IN) is capable of integrating the
viral DNA into the host genome. IN first removes two nucleotides from the 3’ end of both
DNA strands, producing recessed 3’ ends [14]. Then it cuts the host DNA, creating 5’
overhangs. The integration reaction is completed by cellular DNA repair enzymes, which
ligate the ends and fill the gaps. The viral DNA is now integrated in the host DNA as a
provirus. Cellular signals convert the cell from the latent stage to a virus producing stage. The
mechanisms for this conversion are unknown.
1.2.4 Expression of viral proteins
The integrated provirus is flanked by tandem LTRs (see Figure 1). The 5’ LTR contains an
enhancer-promotor, and the 3’ LTR contains a polyadenylation site, similar to a eucaryotic
gene. Transcription of the provirus is done by the cellular polymerase II, resulting in a
primary transcript. The primary transcript is mostly spliced, but some full-length transcripts
occur at this early phase. There are two important functions of the full-length primary
transcript; it serves as the viral genomic RNA that is packaged into virons and it serves as
mRNA for the translation of all the viral proteins.
The HIV-1 promotor is highly regulated by both cellular and viral factors. In a model
for regulation of viral gene expression, the expression is separated into two phases. There is
the early phase, where multiply spliced mRNAs are synthesised. These mRNAs encodes the
non virion proteins Tat, Rev and Nef. This phase is followed by the late phase where an
accumulation of unspliced and singly spliced mRNAs leads to production of the proteins that
are incorporated into virions [15, 16].
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Figure 2. The viral lifecycle. (1) The virus binds to the CD4 receptor on the cell surface by an interaction
between gp120 and CD4. (2) The host cellular membrane fuses with the virion membrane and the virion core is
released into the cytoplasm. (3) DNA is produced from viral RNA by reverse transcription. (4) RNaseH degrades
the RNA. (5) The second strand of DNA is produced by RT. (6) The preintegration complex migrates to the
nucleus. (7) The cellular DNA is cut, and the viral DNA integrated into the host genome by integrase. (8) The
viral DNA is latent in the host genome. (9) Host enzymes transcribe the cellular genes. (10) The RNA is
transported out of the nucleus and processed. (11) Viral polyproteins are synthesised. (12) Some viral proteins
are glycosylated. (13) The viral RNA and viral proteins are assembled into the virion. (14) The virion buds from
the plasma membrane. (15) Maturation of the virion.
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The viral protein Tat activates the transcription of the HIV-1 genes and leads to high levels of
spliced transcripts early after productive infection i.e. the early phase. The Rev protein
regulates the balance of spliced to unspliced and partially spliced mRNAs. Activation by Rev
leads to the late phase of viral expression.
1.2.5 Virion assembly, budding and release
Prior to virion assembly the major structural proteins accumulate inside the plasma
membrane. Then the Gag polyprotein oligomerises [17] and the Gag protein is transported to
the plasma membrane. It is the matrix (MA) domain of the Gag protein that is responsible for
this transport [18]. The Gag polyprotein complex starts forming the inner framework of the
virion and two copies of the viral RNA assemble around a motif in the NC domain of the Gag
polyprotein [19]. The encapsidation process is completed when the tRNALys3 primer
associates with the Pol domain of the Gag-Pol polyprotein and is included in the virion [20].
Maturation of the virion occurs as a coordinated process by which the viral protease cleaves
the Gag-Pol polyprotein in an ordered fashion [21]. F llowing maturation, the Gag and Gag-
Pol polyproteins begin to encapsidate the viral RNA and the plasma membrane forms a lipid
bilayer around the virion. The gp160 is glycosylated and oligomerised in the endoplasmatic
reticulum [22, 23] and transported to the Golgi apparatus. Here the glycoprotein is processed
into gp120 (SU) and gp41 (TM) [24]. Then they associate noncovalently and are transported
to the cell surface [25]. Finally the inner core shell condenses and is linked with the lipid
membrane containing the viral glycoproteins.
1.3 The preintegration complex (PIC)
Following cell infection by HIV-1, the viral proteins remain associated with the viral nucleic
acids in a high molecular weight nucleoprotein complex (preintgration complex, PIC) [12,
26]. After reverse transcription the viral DNA must be transported to the cell nucleus before it
can be integrated into the host genome. This transport of PIC to the nucleus is achieved by
means of a process requiring ATP, but independent of cell division. [27]. The composition of
PIC is relatively well established, but its means of nuclear transport is still under extensive
investigation.
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1.3.1 The composition of PIC
Several different approaches have been used to purify the HIV-1 PIC. The results of these
differing approaches are fairly uniform. The virion protein most stably associated with PIC is
IN [12]. RT, MA and Vpr can also be detected under a number of conditions [10, 11, 13, 28-
30]. Under very limited conditions NC, PR and low amounts of CA have also been detected
[10, 13, 28]. The HIV-1 PIC does not contain high amounts of capsid proteins, a fact that
distinguishes it from the murine leukaemia virus (MLV) PIC [10-13]. A number of cellular
proteins have been shown to associate with PIC. These include importin-a [29, 31]; HMG
I(Y) [32], which is important for PIC activity in vitro; and histones [10].
1.3.2 Nuclear transport of PIC
Transport of the HIV-1 PIC to the nucleus during interphase is a unique feature that
distinguishes HIV-1 and the lentiviruses from other retroviruses. The lentiviruses are not
dependent on the dissolution of the nuclear envelope during mitosis to get access to the
cellular genome [33, 34]. Nuclear import of PIC is in addition believed to be critical for HIV-
1 replication in non-dividing and slowly dividing cells [30, 35-37]. There are three
components of the HIV-1 PIC that are believed to be important for the nuclear import; IN,
Vpr and MA.
IN has been shown to have a role in nuclear import of PIC [29]. IN has a bipartite
nuclear localisation signal (NLS) that is recognised by the importin/karyopherin pathway. A
combination of mutations in this NLS region of IN, in Vpr and in the NLS of MA totally
eliminated the nuclear import of the HIV-1 PIC in P4 cells, but with virus that was only
defective in Vpr and the MA NLS, the import was just partially reduced. This was taken as
proof for the importance of IN in the process of nuclear import.
Vpr is another component of the HIV-1 PIC that is implicated in nuclear import [30,
35]. Vpr bind to karyopherin a, but to a different site than the NLS binding site. This binding
increases the affinity of the karyopherin a and NLS interaction [38]. Vpr has also been shown
to interact with some nucleoporins [39] and to regulate binding of PIC to the nuclear pore
complex [40, 41]. It is not known whether Vpr can function as an independent HIV-1 nuclear
import factor.
MA is the third and most important member of PIC when it comes to nuclear import.
An NLS in the N-terminal region of MA was first identified [37, 42] and believed to
determine the nuclear translocation activity of HIV-1 PIC. This hypothesis was later
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disrupted, when mutations in this NLS had little effect on HIV-1 replication in non-dividing
cells [43, 44]. It has also been shown that the nuclear import function is maintained when MA
has a large N-terminal truncation [45]. These findings questioned the role of MA in the
nuclear translocation process. Recently a new NLS in MA has been discovered [46], called
NLS-2. The NLS-2 is located in the C-terminal region of MA. When both the N-terminal NLS
and NLS-2 in MA were inactivated, the virus was rendered unable to replicate, despite the
presence of both Vpr and IN. This indicates that MA is necessary for the efficient nuclear
import of the HIV-1 PIC in vivo.
1.4 Structure and function of reverse transcriptase
Reverse transcriptase (RT) is a heterodimer consisting of one subunit with molecular weight
of 66 kDa (p66), and one subunit of 51 kDa (p51). The protein is processed from the Gag-Pol
polyprotein by PR during virion assembly [47]. The processing of Gag-Pol occurs in two
steps; first the p66 is cleaved from the polyprotein, and a homodimer is formed. Second, one
of the subunits in the p66 homodimer is cleaved near the C-terminus and the heterodimer is
formed.
Several structures of RT are reported, all found by X-ray crystallography. They share
the same structural features, and differ only in the molecules used together with RT in the
crystal. A schematic model of RT is given in Figure 3.
Kohlstaedt,et al describes an enzyme-inhibitor complex [48]. They divide the
polymerase regions of p66 and p51 into four subdomains denoted “fingers”, “palm”, “thumb”
and “connection” (see Figure 3). The subdomains are arranged differently in each subunit,
thus the heterodimer is asymmetric. This is remarkable, since p51 is formed from a C-
terminal deletion of p66. The major contacts between p51 and p66 occur in the connection
domains. The thumb of p51 contacts the RNase H domain of p66. This interaction may be
required for RNase H activity [49]. In addition the palm of p66 is in contact with the fingers
of p51. In the p51 subunit, the connection domain is rotated such that it occupies the palm and
buries the active site residues. This is consistent with the fact that mutations in the active site
of p51 have little effect on RT activity [50]
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Figure 3. An overview of the RT domains. After PR processes RT from the Gag-Pol precursor to yield a p66
homodimer, a part of the C-terminus is cleaved from one of the subunits to produce the p66/p51 heterodimer.
The structures of the subdomains of p66 have been compared with a right hand and the subdomains are
subsequently designated as palm, thumb and fingers. A connection domain joins the polymerase domain to the
RNase H domain. Asp110 and Asp185,186 are residues involved in catalysis. The viral RNA and the tRNA primer
are positioned in the palm.
An other crystal structure determined for RT [51], describes a DNA-template-primer
complex bound in the cleft region. The cleft is flanked by a putative nucleoside triphosphate
binding site and the RNase H active site. This is consistent with models that suggest that the
polymerase active site and the RNase H active site act coordinately during the synthesis of
minus strand DNA [52]. A higher resolution structure has also been reported by the same
group [53]. This shows the putative catalytic residues Asp110-A p185-Asp186 positioned near
the primer strand 3’ hydroxyl. In this structure , the bound template-primer shows both A- and
B-form regions of DNA separated by a bend. Contacts between the template strand and the
palm and thumb were also noted.
RT is an enzyme with three important enzymatic activities:
-RNA-dependent DNA polymerase
-DNA-dependent DNA polymerase
-Ribonuclease H (RNase H)
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These activities are used to copy the single-stranded RNA-genome of the virus into a double-
stranded DNA molecule that can be integrated into the host genome. The polymerase activity
of RT lies within the N-terminal portion of p66 and the RNase H activity resides in the C-
terminal part of the same subunit.
The catalytic site of RT lies in a cleft in the palm of the p66 subunit (see Figure 3). It
contains the sequence Tyr183-Met184-Asp185-Asp186 (YMDD) in addition to Asp110. Two a-
helices in the thumb of the p66 subunit together with the palm subdomain act as a clamp to
position the template-primer relative to the polymerase active site. The 3’ hydroxyl of the
primer terminus is held close to the catalytically essential Asp110-Asp185- s 186 residues, thus
in position for nucleophilic attack on incoming nucleoside triphosphates. The connection
subdomain of p66 interacts with both the template and p51.
1.5 Structure and function of integrase
Integrase (IN) is an enzyme of 31 kDa, produced from the C-terminal part of Pol after the
processing of the Gag-Pol polyprotein by the HIV-1 protease (PR).
IN comprises three independently folding domains; an N-terminal domain, a catalytic
core domain and a C-terminal domain (see Figure 4). The structures of the separate domains
are known, but the manner in which they interact in the holoenzyme is still not known. This is
because IN has not yet been crystallised, due to its poor solubility.
The first 50 amino acids define the N-terminal domain. A conserved HHCC motif,
similar to certain zinc-binding motifs, is the most significant region of homology in this
family of proteins [54]. The isolated N-terminal of IN has actually been shown to bind zinc at
a 1:1 molar ratio [55, 56]. The zinc-binding is required for folding of the isolated N-terminal
domain and also enhances multimerisation of the full-length IN [56, 57]. The exact function
of the N-terminal domain is not known. It has been suggested that this domain is involved in
DNA-binding [58], but deletion of the N-terminal domain does not affect the DNA-binding
activity of IN [59].
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Figure 4. Model of HIV-1 IN. This model shows the three IN folding domains with known structure. The
region called “tail” refers to the last 18 amino acids at the C-terminus. The structure of this region is not known.
The conserved and catalytically important residues are indicated with corresponding residue numbers. This
figure is adapted from Asante-Appiah and Skalka [60].
The structure of the N-terminal domain of IN has been solved by NMR [61]. It is
composed of four a-helices with a hydrophobic core stabilising the lower region of the
monomer. The upper part of the monomer is stabilised by the coordination of zinc to the
HHCC motif (see Figure 5a). The N-terminal domain is a dimer with a hydrophobic dimer
interface. This dimer resembles several helix-turn-helix DNA binding domains. It is
nevertheless not obvious that the N-terminal domain of IN is binding DNA. The second helix
of the IN N-terminal domain is part of the dimer interface as opposed to the corresponding
DNA binding helix in helix-turn-helix DNA domains.
The catalytic core domain is a well conserved domain among retroviral integrases and
contains a DD(35)E motif. The residues in this motif; Asp64, Asp116 and Glu152, are key
residues in the active site [62, 63]. It has been proposed that these residues coordinate divalent
metal ions critical for catalysis [62].  Mutations of any of these residues diminish or abolish
the catalytic activity of IN [62, 64].
The structure of the catalytic core domain has been determined by X-ray
crystallography [65]. As a dimer it is spherical in shape, with each monomer forming one
hemisphere. Each monomer comprises a central five-stranded ß-sheet and six helices (see
Figure 5b). The conserved acidic residues (Asp64, Asp116 and Glu152) are located in close
proximity in the structure. But unexpectedly, the two catalytic sites are located on opposite
sides of the spherical dimer, in a distance higher then the sites of insertion on the target DNA.
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Figure 5. Structure of the different IN domains.  a) Structure of a monomer of the N-terminal zinc-binding
domain of IN. This structure is determined by NMR [61]. The zinc atom is showed in green and the coordinating
His and Cys residues in blue and yellow respectively. b) Structure of a monomer of the catalytic core domain of
IN. The structure of this domain is determined by X-ray crystallography [65]. c) Structure of a monomer of the
C-terminal domain of IN. This structure is determined by NMR [66]. The three molecules are visualised using
Raswin 2.6 and the files 1wjc, 1itg and 1qmc from Brookhaven National Laboratory Protein Data Bank.
The C-terminal domain is less conserved then the other domains. This region
possesses non-specific DNA binding activity similar to that of the full-length integrase [67-
71]. It has therefore been suggested that this domain is responsible for the binding of IN to the
host genome.
The structure of the C-terminal domain was determined by using NMR [66, 72]. The
structure is dimeric, with each monomer composed of a five-stranded ß-barrel (see Figure 5c).
Stacking of ß-strands 2, 3 and 4 of each monomer in an antiparallell configuration forms the
dimer. The dimer has a large saddle-shaped cleft that contains a number of positively charged
residues. This cleft has the proper shape and size to accommodate double-stranded DNA.
IN mediates covalent linkage of linear double-stranded viral DNA to the host cell
genome, thus possesses both DNA cleavage and joining activities. IN also mediates the
reverse reaction i.e. disintegration in vitro [73]. This observation is consistent with the idea
that the mechanism of integration involves a concerted mechanism and not a protein-DNA
intermediate. Studies in vitro with deletion and site-specific point mutations in IN show that
Asp64, Asp116 and Glu152 are essential for cleavage, joining and disintegration [74]. This
finding, together with the three-dimensional model for the catalytic domain of IN, indicates
that this viral enzyme carries out all three reactions within a single active site.
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1.6 The  RT – IN interaction, and its study
Both RT and IN are known to be present in the HIV-1 PIC. In this complex, all the
components need to be kept in close proximity. It is therefore very likely that direct
interactions between RT and IN occur. An important question in this regard is where IN is
located during the reverse transcription. Recent studies have shown that IN is essential for the
initiation of reverse transcription in infected cells [75]. Thi  strengthens the theory that there
is a direct physical interaction between RT and IN. Several other observations also suggest
that RT and IN may form a heterodimeric complex: The two proteins are known to coexist as
a complex in some retroviruses [76, 77]. Further, the C-terminal domain of RT (RNase H) and
the central core domain of IN are structurally similar [65, 78]. Finally, IN and RT can be
coimmunoprecipitated with antibodies to either protein in murine leukaemia virus [79].
There are a number of different techniques developed to study protein-protein
interactions. A description of all of them would be too extensive for this thesis. Therefor a
selection of techniques believed to be applicable to the problem of detecting RT-IN
interactions has been done. These techniques are described below.
1.6.1 Coimmunoprecipitation
Coimmunoprecipitation is a classical method of detecting protein-protein interactions and has
been used in literally thousands of experiments. It exists a variety of different approaches that
shares the common feature of using a precipitating antibody to test for physical interactions
between proteins. In a typical experiment cells are lysed and a whole-cell extract is prepared
under nondenaturing conditions. Following, the protein is precipitated form the lysate with a
solid-phase affinity matrix (i.e. protein G-Sepharose) and the precipitate is tested for the
presence of a second specifically associated protein. This method can be used for either native
or epitope-tagged proteins for which antibodies are available. It is also possible to use
recombinant proteins that have been engineered to bind with high affinity to a molecule that
can be coupled to a solid-phase matrix. The presence of an associated protein is detected by
separating the precipitated proteins by SDS-PAGE and Western blotting with an antibody
recognising the putative associated protein. It is very important to add controls that test the
specificity of interaction.
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1.6.2 The yeast two-hybrid system
The yeast two-hybrid system is a yeast-based method to detect protein-protein interactions in
vivo [80, 81]. It is based on the fact that many transcriptional activators consist of two
modular domains; a DNA-binding domain and an activation domain. Normally these domains
reside in the same protein, but it has been shown that separated domains can be able to
assemble a functional transcriptional activator when brought into close proximity. The most
used two-hybrid system is based on a GAL4 binding domain. The GAL4 protein is a
transcriptional activator required for galactose utilisation in Saccharomyces cerevisiae. Th
N-terminal part of the protein is DNA-binding, and the C-terminal part activates transcription.
Chimeric proteins can be made between the GAL4 domains and the proteins under
investigation, using standard molecular biology cloning techniques. Introduction of the two
plasmids encoding the chimeric proteins into a yeast strain with a reporter gene under control
of the GAL4 activator allows for the detection of weak and transient interactions.
1.6.3 Physical chemical methods
BIAtechnology from Biacore AB is a physical-chemical approach for detecting protein-
protein interactions. BIAtechnology enables detection of interactions between molecules, in
real time, without the use of labels. BIAtechnology relies on the phenomenon of surface
plasmon resonance (SPR) which occurs when surface plasmon waves are excited at a
metal/liquid interface. Light is directed at, and reflected from, the side of the surface not in
contact with sample, and SPR causes a reduction in the reflected light intensity at a specific
combination of angle and wavelength. Molecular binding events cause changes in the
refractive index at the surface layer, which are detected as changes in the SPR signal. In
general, the refractive index change for a given change of mass concentration at the surface
layer, is practically the same for all proteins and peptides, and is similar for glycoproteins,
lipids and nucleic acids.
1.6.4 Enzyme Linked Immunosorbent Assays (ELISA)
ELISA was first described in 1971 as a method for detecting soluble antigens and antibodies.
The assay method has been very successful owing to its sensitivity, speed and reproducibility
of the assays. In addition to detecting soluble antigens and antibodies, ELISA can be used to
detect protein-protein interactions. There are at least two different formats for detecting such
Introduction
15
interactions. The first format involves coating with one of the proteins under investigation,
blocking, adding the second protein, following an antibody for the second protein and
addition of a secondary antibody conjugated to an enzyme. In case of an interaction,
consequent addition of substrate will lead to development of colour. In the second format, the
coating is done with an antibody for the first protein, following addition of the protein. The
rest of the procedure is the same as in the first format. These two formats require small
amount of protein, and are relatively easy to perform.
1.7 Aims of study
The HIV-1 proteins RT and IN are known to act together in the PIC. Several studies have
been performed, trying to establish an interaction between the two proteins. By employing the
yeast two-hybrid system, no such interaction could be detected [82]. Recently, however, an
interaction has been detected with an in vitro binding assay. [75].
These are only two of several different ways to study protein-protein interactions. The
sources of protein for these studies can also vary. The aims of this study are to produce HIV-1
RT and IN by in vitro transcription and translation and to see if the resulting proteins can be
used for protein-protein interaction studies. Because the ELISA method requires small
amounts of protein, this particular method was chosen.
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2 Materials and methods
2.1 Enzymes
Name Concentration Supplier
BamHI 10 U/µl Promega
EcoRI 12 U/µl Promega
Rnase 1 mg/ml Boeringer Mannheim
Taq polymerase 5 U/µl Promega
SacI 10 U/µl Promega
T4 DNA Ligase 3 U/µl Promega
2.2 Plasmids
pCITE-5b(+) (3.7 kb) from Novagene (Figure 6).
Figure 6. The plasmid pCITE-5b(+) from Novagene.
pSVC21 containing the entire HIV-1 genome from the HxB2 clone (gift from William A.
Haseltine).
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2.3 Antibodies
Name Supplier
Anti-RT antibodies: 8C4, 11B7 Szilvay,et al [83]
Anti-IN antibodies: 8E5, 8G4 Nilsen,et al [84]
Biotin conjugated anti-mouse Dako A/S
Horse radish peroxidase conjugated streptavidinAmersham
Horse radish peroxidase conjugated anti-mouseAmersham
2.4 Bacterial strains
E. coli Xl1Blue (recA1, endA1, gyrA96, thi, hsdR17 (rk[+], mk[+]), supE44, relA1,
{lambda}[-], lac, [F’, proAB, lacIqC{Delta}M15, tn10 (tet[R])])
2.5 Growth media
Bacto-Agar, peptone, tryptone and yeast extract are from Difco.
The ampicillin is from Sigma.
LB-medium (Luria-Bertani):
10 g Tryptone
5 g Yeast extract
10 g NaCl
ddH2O were added up to 1 litre, and the solution was autoclaved.
Agar plates were made by adding 20 g/litre Bacto-agar before autoclaving the solution.
To make ampicillin plates, 50 µg/ml of ampicillin was added after autoclaving.
SOC-medium:
2% Tryptone
0.5 % Yeast extract
10 mM NaCl
2.5 mM KCl
10 mM MgCl2
10 mM MgSO4                  Autoclaved
20 mM Glucose
The MgCl2, the MgSO4 and the glucose are added from sterile 1 M stock solutions
immediately before use.
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2.6 Solutions and buffers
2.6.1 Produced solutions and buffers
Name Description Comment
0.5 M Tris-HCl, pH 6.8 6 g Tris is dissolved in 60 ml dH2O
pH is adjusted to 6.8 with HCl
Water is added to 100 ml
1 % Gelatine 10 g gelatine
Dissolved in 1 litre 1 X PBS
1 X Blotting buffer 7 parts of dH2O
2 parts of Methanol
1 part of 10 X Blotting buffer
1.5 M Tris-HCl, pH 8.8 27.23 g Tris is dissolved in 80 ml dH2O
pH is adjusted to 8.8 with HCl
Water is added to 150 ml
10 X Blotting buffer 144 g Glycine
30.3 g Tris
Water is added to 1 litre
The solution is autoclaved
10 X PBS 80 g NaCl
2 g KCl
14.4 g Na2HPO4
2.4 g KH2PO4
10 X Running buffer 60 g Tris base
288 g Glycine
20 g SDS
Water is added to 2 litres
10 X TBS 300 ml NaCl
200 ml Tris-HCl, pH 7.5
500 ml dH2O
30 % acrylamide, bis 87.6 g acrylamide
2.4 g bisacrylamide
Water is added to 300 ml
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Name Description Comment
3M Sodiumacetate, pH 4.8 40.81 g sodium acetate
80 ml H2O
pH is adjusted to 4.8 with glacial acetic
acid
Water is added to 100 ml
Blocking solution 1 g Ficoll
1 g Polyvinylpyrrolidon
10.3 g Boric acid
1.1 g NaOH
8.81 g NaCl
0.4 g NaN3
0.5 g Gelatine
1 ml Nonidet P-40 (NP-40)
1 L dH2O
15 g BSA is put on top
The solution is then put on a
magnetic stirrer until most of
the BSA is dissolved, and then
filtrated.
GTE-solution 50 mM glucose
20 mM Tris-HCL pH 8
10 mM EDTA
The solution is autoclaved and
stored at 4°C
KAc-solution 29.5 ml glacial acetic acid
KOH pellets until a pH of 4.8 is reached
H2O to 100 ml
Stored at room temperature
NaOH-solution 0.2 N NaOH
1 % SDS
Freshly prepared
Sample buffer 200 mM Tris-HCL, pH 6.8
4 % SDS
20 % glycerol
Pyronin B (saturated solution in
ethanol)
H2O to 100 ml
TE-buffer 10mMTris-HCL pH 8
1 mM EDTA pH 8
The solution is autoclaved
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2.6.2 Purchased solutions and buffers
Name Supplier
10 X Ligation buffer Promega
10 X Multicore buffer Promega
10 X PCR buffer Promega
6 X Loading buffer Promega
Big Dye PE Biosystems
dATP Promega
dCTP Promega
dGTP Promega
dTTP Promega
2.7 Molecular weight standards
Name Supplier
pGEM DNA Promega
l/HindIII DNA Promega
Prestained Protein Marker Broad Range New England Biolabs
HIV-1 IN (23 mg/ml) Provided and purified by Professor Dag E. Helland
HIV-1 RT-His tag (0.75 mg/ml, 75% pure) Provided and purified by Professor Dag E. Helland
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2.8 Chemicals
Name Formula Supplier
2-Mercaptoethanol C2H6OS Merck
Acrylamide Merck
Agarose NA Pharmacia Biotech.
Ammonium persulphate Biorad
Bisacrylamide Biorad
Bovine Serum Albumine, (BSA) Sigma
D(+)-Glucose-Monohydrate C6H12O6·H2O Merck
di-Sodium hydrogen phosphate dihydrate Na2HPO4 Merck
Ethanol Arcus produkter
Ethylenediaminetetraacetic acid, (EDTA) C10H14N2O8Na2·2H2O Sigma
Ethylphenyl polyethylene glycol, (Nonidet P-40) United States Biochemical corp.
Ficoll 400 Sigma
Gelatine Difco
Glycerol C3H8O6 Merck
Glycine H2NCH2COOH Merck
Hydrochloric acid HCl Merck
Low-melting-point agarose BRL
Magnesium chloride hexahydrate MgCl2·6H2O Merck
Magnesium sulphate MgSO4 Merck
Methanol CH4O Prolabo
N,N,N’,N’-Tetramethylendiamin, (TEMED) C6H16N2 Merck
Polyoxyethylene sorbitan monolaurate, (Tween-20) Sigma chemical co.
Polyvinylpyrrolidon Merck
Potassium chloride KCl Merck
Potassium dihydrogen phosphate KH2PO4 Merck
Potassium hydroxide pellets KOH Merck
Sodium azide NaN3 Riedel-De Haën ag.
Sodium chloride NaCl Merck
Sodium dodecyl sulphate, (SDS) CH3(CH2)11SO4Na United States Biochemical corp.
Sodium hydroxide pellets NaOH Merck
Tris NH2C(CH2OH)3 United States Biochemical corp.
Materials and methods
22
2.9 Kits
Name Supplier
TNT® T7 Quick Coupled Transcription / Translation systemPromega
Quiagen megaprep Quiagen
2.10 Electrical equipment
Description Name Supplier
Centrifuge Sorwall RC5B Refrigerated Superspeed CentrifugeSorwall
Developer Fuji X-ray film developer RGII Fuji
Electroporator Gene Pulsar Biorad
ELISA-plate reader Multiscan MS Labsystems
Eppendorf centrifuge Centrifuge A 14 Jouan
Incubator B5028 Heraeus
Incubator with shaking HT Infors AG
Incubator with shaking, eppendorfThe momixer eppendorf
PCR-machine 2400 thermocycler Perkin Elmer
Power supply Model 200/2.0 Biorad
Sequencer ABI PRISM 377 DNA Sequencer Applied Biosystems
Spectrophotometer UV-1201 uv-vis spectrophotometer Shimadzu
Vacuum centrifuge SpeedVac SVC100 Savant
Vortexer Model K-550-GE Bender & Hobein AG
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2.11 Miscellaneous
Description Supplier Comment
Acrylamide gel equipment Biorad Mini-PROTEAN 3
Agarose gel equipment Owl Separation Systems Inc.Model B1
Autoradiography film Amersham pharmacia biotechHyperfilm
Biotin-Lysyl-tRNA Promega Transcend™ tRNA
Blotting equipment Biorad Mini Trans-Blot Cell
ECL Western blotting detection reagentsAmer ham Life Science
Electroporation cuvettes Biorad Gene Pulser ® Cuvette
Filterpaper Whatman Chromatography paper 3MM Chp
Immunoplates Nunc F96 MaxiSorp Nunc-Immuno Plates
Nitrocellulose membrane Schleicher & Schuell Protran
2.12 Bacteriological methods
2.12.1 Preparation of electro-competent E.coli cells
One colony of E.coli Xl1Blue was inoculated in 5 ml of LB-medium and left to grow over
night (37ºC, moderate shaking). 2.5 ml of this culture was inoculated in 500 ml LB-medium
and left to grow at 37°C and with moderate shaking to an OD600 of approximately 0.5. The
cells were chilled on ice, transferred to four pre-chilled GSA centrifuge tubes and centrifuged
at 4200 rpm for 20 minutes at 4°C. The supernatants were poured off, and the pellets
dissolved in 1.25 ml ice-cold water before adding 125 ml of water to each tube and
centrifuging again as before. The supernatants were poured off again and the pellets dissolved
in the remaining liquid. Another 125 ml of cold water was added, and the liquid was
centrifuged under the same conditions. After the supernatants were poured off, the pellets
were dissolved and 10 ml of ice-cold 10% glycerol was added. Another centrifugation was
performed at 4200 rpm for 10 minutes at 4°C. The supernatants were poured off and the
pellets dissolved in the remaining glycerol. The cells were then aliquoted and stored at –70°C.
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2.12.2 Transformation of cells
The cells were transformed by electroporation. The electroporator (Biorad Gene Pulsar) was
adjusted to deliver a pulse of 2.5 kV. An appropriate amount of plasmid DNA was mixed with
100 µl of electro-competent cells. The mixture was transferred to a pre-chilled electroporation
cuvette and the cuvette was placed in the apparatus. A pulse was applied, following addition
of 1 ml of SOC-medium. Then the mixture was transferred to a sterile eppendorf-tube and
incubated for 45 minutes at 37°C and moderate shaking. 100 µl of the culture was plated out
on a LB-plate containing ampicillin. The rest of the bacteria was spun down, and redissolved
in 100 µl SOC-medium. This was also plated out on a LB-plate containing ampicillin. The
plates were incubated at 37°C over night.
2.12.3 Isolation of plasmids from bacteria
Alkaline lysis minipreparation
For small-scale preparations of plasmid DNA (for detection and characterisation), the alkaline
lysis method was used. One single bacterial colony was scraped from a LB-plate and
inoculated into 5 ml of LB-medium containing the appropriate antibiotic. The culture was
grown to saturation over night, at 37°C and moderate shaking. 1.5 ml of the culture was spun
down for 20 seconds at 13000 rpm and the supernatant removed. The pellet was resuspended
in 100 µl GTE-solution and left to stand for 5 minutes at room temperature. 200 µl of NaOH-
solution was added, the solution was gently mixed by flicking the tube and the tube was
placed on ice for 5 minutes. After this, 150 µl of KAc-solution was added, the mixture was
vortexed and placed on ice for 5 minutes. The solution was then centrifuged for 3 minutes at
13000 rpm to pellet cell debris and chromosomal DNA. The supernatant was transferred to a
fresh tube, mixed with 0.8 ml 96 % ethanol and left in room temperature for 2 minutes to
precipitate nucleic acids. Centrifuging for 1 minute at 13000 rpm pelleted these nucleic acids.
The supernatant was removed, and the pellet washed with 70 % ethanol. The pellet was dried
in a vacuum centrifuge before resuspending in 30 µl TE-buffer.
The plasmids were characterised by restriction enzyme analysis (1 to 5 µl of plasmid solution
was used), run on an agarose gel containing ethidium bromide and visualised under UV-light.
Following, the gel was photographed and the picture kept for further analysis.
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Quiagen megapreparation
To obtain a high yield of very pure plasmid, the Quiagen megaprep protocol was used. The
protocol was followed as the manufacturer recommends.
The concentration of the plasmid solution was determined using agarose gel-electrophoresis
and UV spectrophotometry.
The following formula was used to calculate the double stranded DNA concentration:
DNA concentration = A260
. 50 µg/ml . Dilution
2.13 PCR amplification of the RT and IN coding regions
2.13.1 The PCR reaction
The coding regions of RT and IN with different restriction enzyme cutting sites were
amplified by PCR. The following primers were used:
Name Sequence Length RE site
LWRT5 5’ CC GGG GAT CCC ATT AGC CCT ATT GA 3’ 25 bp BamH1
LWRT3 5’ G GGA ATT CCG TAG TAC TTT CCT GAT TC 3’ 27 bp EcoR1
LWIN5 5’ CC GGG GAT CCG TTT TTA GAT GGA ATA GA 3’28 bp BamH1
LWIN3 5’ G GGA GCT CGA CTA ATC CTC ATC CTG CT 3’ 27 bp Sac1
The plasmid pSVC21 containing the entire HIV-1 genome was used as template and the
following PCR reactions were set up:
Reverse transcriptase
5 µl 10X PCR buffer
5 µl 500 µM dNTP-mix
1 µl 5U/µl Taq polymerase
1.5 µl 15 mM LWRT5 primer
1.5 µl 15 mM LWRT3 primer
1 µl 170 pg/µl pSVC21
20 µl ddH2O
35 µl
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Integrase
5 µl 10X PCR buffer
5 µl 500 µM dNTP-mix
1 µl 5U/µl Taq polymerase
1.5 µl 15 mM LWIN5 primer
1.5 µl 15 mM LWIN3 primer
1 µl 170 pg/µl pSVC21
20 µl ddH2O
35 µl
Two parallel reactions were run for each amplification. The thermal cycling was performed
on a Perkin Elmer 2400 termocycler. The PCR cycling program is described in Figure 7.
Figure 7. Description of the PCR cycling program. a) 8 minutes of denaturation at 94°C. b) 30 seconds at
94°C. c) 60 seconds annealing starting at 60°C and increasing 0.4°C per cycle. d) 2 minutes extension at 72°C. e)
8 minutes at 72°C. f) Cooling of the samples at 4°C.
2.13.2 Purification of the PCR products
The products from the two parallel PCR reactions were pooled giving approximately 60 µl of
PCR product for both IN and RT. 6 µl 3 M NaAc, pH 4.8 was added before vortexing.
Following, 132 µl of ice-cold 100 % ethanol was added. The mix was vortexed and left at for
30 minutes at -20°C. The samples were then centrifuged at maximum speed in an eppendorf
centrifuge, and the supernatant removed. 1 ml 70 % ethanol was added, and the centrifugation
was repeated. After removing the supernatant again, the pellet was dried for 10 minutes in a
vacuum centrifuge. The pellet was then dissolved in 30 µl ddH2O.
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2.14 Construction of in vitro transcription and translation vectors encoding IN
and RT
The two in vitro transcription vectors were made by inserting the genes for HIV-1 integrase
(IN) and HIV-1 reverse transcriptase (RT) into the in vitro transcription and translation vector
pCITE-5b(+) from Novagen. The genes were amplified from pSVC21 (containing the entire
HIV-1 genome from the HxB2 clone) by PCR (see 2.13).
2.14.1 Digestion with restriction enzymes
The following reactions were performed:
pCITE-5b(+) cut with EcoR1 and BamH1
10 ml  0.5 µg/µl pCITE-5b(+)
2 ml 10X Multicore Buffer
1 ml 12 U/ml EcoR1
1 ml 10 U/ml BamH1
6 ml ddH2O
20 ml
pCITE-5b(+) cut with Sac1 and BamH1
10 ml 0.5 µg/µl pCITE-5b(+)
2 ml 10X Multicore Buffer
1 ml 10 U/ml Sac1
1 ml 10 U/ml BamH1
6 ml ddH2O
20 ml
The PCR products were incubated with an excess of restriction enzymes:
Reverse transcriptase PCR product cut with EcoR1 and BamH1
5 ml reverse transcriptase PCR product
2 ml 10X Multicore Buffer
3 ml 12 U/ml EcoR1
3 ml 10 U/ml BamH1
7 ml ddH2O
20 ml
Materials and methods
28
Integrase PCR product cut with Sac1 and BamH1
5 ml integrase PCR product
2 ml 10X Multicore Buffer
3 ml 12 U/ml Sac1
3 ml 10 U/ml BamH1
7 ml ddH2O
20 ml
All four reactions were incubated at 37°C over night and the reactions were stopped by
adding 5 ml 6X loading buffer.
2.14.2 Electrophoresis in low meltingpoint (LMP) agarose
A 1 % LMP agarose gel was used. A total amount of 25 ml from the restriction enzyme
cutting reaction was applicated on the gel. The gel was run for 1.5 hours at 100 V. The bands
were visualised with ethibium bromide in UV- light. The desired bands were cut out from the
gel and put in a sterile eppendorf tube.
2.14.3 Ligation in LMP agarose
The bands from the LMP agarose gel-electrophoresis were melted at 70°C for 10 minutes.
The following ligation reactions were performed:
Reverse transcriptase
10 ml pCITE-5b(+) cut with EcoR1 and BamH1
5 ml RT PCR product cut with EcoR1 and BamH1
10 µl ddH2O
This was mixed thoroughly by pipetting up and down and
3 ml 10 X Ligation buffer
2 ml T4 DNA ligase
was added. The reaction was incubated at room temperature over night.
Kept at 70°C
37 °C
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Integrase
10 ml pCITE-5b(+) cut with Sac1 and BamH1
5 ml IN PCR product cut with Sac1 and BamH1
10 µl ddH2O
This was also mixed thoroughly by pipetting up and down and
3 ml 10 X Ligation buffer
2 ml T4 DNA ligase
was added. This reaction was also incubated at room temperature over night.
After the incubation, the reactions were heated to 70°C and 60 ml 70°C d H2O was added to
each reaction. 10 ml of this was used to transform 100 l electro-competent E.coli cells. After
transformation and identification of positive clones, the plasmids were characterised by
restriction enzyme analysis and purified.
2.14.4 Sequencing of constructs
The following primers were used in the sequencing reactions:
Name Sequence Length
CITE 5’ GGG GAC GTG GTT TTC CTT TG 3’ 20 bp
T7 terminator5’ GCT AGT TAT TGC TCA GCG G 3’ 19 bp
These primers are flanking the multiple cloning sites of the plasmid pCITE-5b(+).
The following reactions were set up:
 pCITE-RT forward
4µl Big Dye
2µl 0.5 µg/µl pCITE-RT
1.6 µl 1µM CITE primer
2.4 µl ddH2O
10 µl
pCITE-RT reverse
4µl Big Dye
2µl 0.5 µg/µl pCITE-RT
1.6 µl 1µM T7 terminator primer
2.4 µl ddH2O
10 µl
Kept at 70°C
37 °C
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pCITE-IN forward
4µl Big Dye
2µl 0.5 µg/µl pCITE-IN
1.6 µl 1µM CITE primer
2.4 µl ddH2O
10 µl
pCITE-IN reverse
4µl Big Dye
2µl 0.5 µg/µl pCITE-IN
1.6 µl 1µM T7 terminator primer
2.4 µl ddH2O
10 µl
The reagents were mixed in PCR tubes and spun down in an eppendorf centrifuge. Then the
thermocycling was performed as follows: After an initial denaturing step at 94°C for 5
minutes, 25 cycles with 10 seconds at 96°C, then 5 seconds at 50°C following 4 minutes at
60°C was run.
To precipitate the DNA, 2 µl 3M sodium acetate pH 4.6, 50 µl 95% ethanol and the DNA was
mixed, the tubes vortexed and incubated on ice for 10 minutes. After the incubation, the
samples were centrifuged at 13000 rpm for 20 minutes. The supernatants were removed with
suction and the pellets were rinsed with 250 µl 70% ethanol. The samples were centrifuged
again at 13000 rpm, this time for 5 minutes. The ethanol was removed and the pellets dried in
a vacuum centrifuge for 15 minutes.
The sequencing was performed on an ABI PRISM 377 DNA Sequencer at the Sequencing
Facility at the University of Bergen.
2.15 In vitro transcription and translation
2.15.1 Production of reverse transcriptase and integrase in vitro
The two proteins were produced in vitro with TNT® T7 Quick Coupled Transcription /
Translation System from Promega. They were visualised after Western blotting by using
Enhanced Chemiluminiscence (ECL).
The following reactions were set up:
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Negative control (no DNA added):
40 µl TNT Quick Master Mix
1 µl 1 mM Methionine
9 µl Nuclease free water
50µl
Reverse transcriptase:
40 µl TNT Quick Master Mix
1 µl 1 mM Methionine
2 µl  (0,5 µg/µl) pCITE-RT
7 µl Nuclease free water
50 µl
Integrase :
40 µl TNT Quick Master Mix
1 µl 1 mM Methionine
2 µl  (0,5 µg/µl) pCITE-IN
7 µl Nuclease free water
50 µl
The reactions were incubated at 30°C for 1 hour, and then kept at –20°C. The proteins were
characterised by SDS-PAGE and Western blotting.
2.16 Protein methods
2.16.1 SDS-PAGE
The separating gels were made after the following table:
8 % gel 10 % gel 12 % gel 15 % gel
ddH2O 4.55 ml 4.1 ml 3.35 ml 2.4 ml
1.5 M Tris-HCl, pH 8.82.5 ml 2.5 ml 2.5 ml 2.5 ml
10 % SDS 0.1 ml 0.1 ml 0.1 ml 0.1 ml
30 % acrylamide, bis2.8 ml 3.35 ml 4.0 ml 5.0 ml
10 % APS 50 µl 50 µl 50 µl 50 µl
TEMED 5 µl 5 µl 5 µl 5 µl
The APS and the TEMED were added just before use.
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Stacking gel:
6.1 ml ddH2O
2.5 ml 0.5 M Tris-HCl, pH 6.8
0.1 ml 10 % SDS
1.3 ml 30 % acrylamide, bis
50 µl APS
10 µl TEMED
The stacking gel solution was added after the separating gel has solidified
The samples were added sample buffer and boiled for 5 minutes at 95°C. Th y were then
cooled on ice before loading on the gel. The gels were run at 100 V until the colour front has
reached the bottom of the gel.
2.16.2 Western blotting
The gel and a nitro-cellulose membrane were placed between 4 filter papers and two “pads”
and placed in a blotting chamber. The chamber was filled with 1X blotting buffer and placed
on ice. The blotting was done at 100 V for 45 minutes. The membrane was then rinsed two
times with TBS and incubated in Blocking solution for 1 hour to block the rest of the protein
binding sites on the membrane. After the blocking procedure, the membrane was rinsed
quickly two times in TBS-Tween (0.05 % Tween 20), then rinsed for 15 minutes and two
times 5 minutes. Next the membrane was incubated with a primary antibody over night at 4°C
or for 1 hour at room temperature. The membrane was then rinsed quickly two times, then for
15 minutes and two times 5 minutes following 1 hour incubation with a secondary antibody
conjugated to POD. The membrane was then washed again quickly three times with TBS-
Tween and then for 15 minutes. The last rinsing was done two times 5 minutes with TBS. The
membrane was now ready to be developed.
2.16.3 Detection of proteins on Western blots
The detection of proteins on Western blots was done with ECL™ Western blotting detection
reagents from Amersham Life Science. After the incubation with secondary antibody
conjugated to POD and subsequent rinsing, the membrane was incubated for 1 minute in a
mix of 0.5 ml detection solution 1 and 0.5 ml of detection solution 2. Following incubation,
the membrane was wrapped in plastic and placed in an X-ray film cassette, protein side up. It
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was important to avoid air-bubbles. The rest of the procedure was performed in the dark. A
sheet of audioradiography film was placed on top of the plastic-wrapped membrane, and
exposed for 10 minutes. The film was replaced with a new one, and the exposed film was
developed. The second film was exposed for about 20 hours.
2.17 The ELISA procedure
Two different enzyme-linked immunosorbent assays were performed for detection of RT-IN
interaction (modified from Greenway,t al [85]).
The first assay involves interaction of RT with immobilised IN, while the second assay
involves interaction of IN with immobilised RT. In the first case, 96-well polystyrene
microtiter plates were coated with 50 µl of the in vitro translation reaction with IN, and with
the negative control reaction as a control. Both were diluted in PBS (See F gure 8a for
details). The coating was performed over night at 4°C. The wells were then washed three
times with PBS-Tween. To block the remaining binding sites, 150 µl of 1% gelatine dissolved
in PBS was added to each well, and the plates were incubated for 1 hour at 37°C. After further
washing with PBS-Tween, a second coating step was performed. Here 50 µl of the in vitro
translation reaction with RT diluted in PBS or PBS alone was added to each well (See Figure
8b for details). The plates were incubated for 2 hours at 37°C. Following washing with PBS-
Tween, anti-RT antibodies 8C4 and 11B7 [83] diluted 1:100 in PBS were added to each well
(50 µl per well), and the plates were incubated for 1.5 hours at 37°C. Wells were again
washed as described above and then incubated with anti-mouse Ig conjugated to biotin
(diluted 1:1000), 50 µl per well. The incubation was done for 1 hour at 37°C. Following
further washing steps, the wells were incubated for 30 minutes at 37°C with streptavidin-HRP
diluted 1:1000 in PBS, 50 µl per well. Binding was detected by using o-phenyle ediamine as
the substrate. The reaction was stopped after 15 minutes by adding 100 µl of 1M H2SO4.
Absorbance was measured by using a plate reader at 492 nm.
Concerning the second case, 96-well polystyrene microtiter plates were coated with 50
µl of the in vitro translation reaction with RT, and also here the negative control reaction as a
control. Both were diluted in PBS (see Figur 8a for details). The coating was performed
over night at 4°C. The wells were then washed three times with PBS-Tween. To block the
remaining sites of the wells, 150 µl of 1% gelatine dissolved in PBS was added to each well,
and the plates were incubated for 1 hour at 37°C. After further washing with PBS-Tween, a
second coating was also here performed. 50 µl of the in vitro ranslation reaction with IN
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diluted in PBS or PBS alone was added to each well (see Figure 8b for details). The plates
were incubated for 2 hours at 37°C. Following washing with PBS-Tween, anti-IN antibodies
8G4 and 8E5 [84] diluted 1:100 in PBS were added to each well (50 µl per well), and the
plates were incubated for 1.5 hours at 37°C. The rest of the procedure was performed as
described above.
A B C D E F G H I J K L
1
2
3
50 µl
1:2
IN from
pCITE-IN
50 µl
1:4
IN from
pCITE-IN
50 µl
1:8
IN from
pCITE-IN
50 µl
1:16
IN from
pCITE-IN
50 µl
1:32
IN from
pCITE-IN
50 µl
1:2
RT from
pCITE-RT
50 µl
1:4
RT from
pCITE-RT
50 µl
1:8
RT from
pCITE-RT
50 µl
1:16
RT from
pCITE-RT
50 µl
1:32
RT from
pCITE-RT
4
50 µl
1:2
Negative
control
50 µl
1 x PBS
50 µl
1 x PBS
50 µl
1 x PBS
50 µl
1 x PBS
50 µl
1:2
Negative
control
50 µl
1 x PBS
50 µl
1 x PBS
50 µl
1 x PBS
50 µl
1 x PBS
5
50 µl
Purified
RT
10 µg
50 µl
Purified
RT
5 µg
50 µl
Purified
RT
2.5 µg
50 µl
Purified
RT
1.25 µg
50 µl
Purified
RT
0.625 µg
50 µl
Purified
IN
10 µg
50 µl
Purified
IN
5 µg
50 µl
Purified
IN
2.5 µg
50 µl
Purified
IN
1.25 µg
50 µl
Purified
IN
0.625 µg
6 50 µl
1 x PBS
50 µl
1 x PBS
50 µl
1 x PBS
50 µl
1 x PBS
50 µl
1 x PBS
50 µl
1 x PBS
50 µl
1 x PBS
50 µl
1 x PBS
50 µl
1 x PBS
50 µl
1 x PBS
7
8
Figure 8a. Overview of the first coating step in the ELISA-procedure. Overview of the proteins added in the
first coating.
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Figure 8b. Overview of the second coating step in the ELISA-procedure. Overview of the proteins added in
the second coating.
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3 Results
3.1 Production of in vitro translation vectors
3.1.1 Amplification of coding regions by PCR
In order to make the HIV-1 proteins RT and IN by in vitro transcription and translation, the i
vitro translation vector pCITE-5b(+) was chosen. The first step in this process was to amplify
the coding regions of the RT and IN genes. These regions were amplified by PCR from the
plasmid pSVC21 containing the complete HIV-1 HxB2 genome. Since there were no
appropriate cleavage sites for restriction enzymes flanking the coding regions, new ones had
to be designed in the primers. A cleavage site for BamHI was introduced in the 5’ end for both
the genes. For RT, an EcoRI site was introduced in the 3’end. These sites enable in-frame
cloning of RT into the vector pCITE-5b(+). IN has a cleavage site for EcoRI in the coding
region of the gene, therefore a cleavage site for SacI was chosen. With these cleavage sites,
also IN can be cloned in the correct reading frame into the vector pCITE-5b(+).
Two identical PCR reactions were run for each primer pair, as described in Methods (2.13).
After the PCR-reactions, 2 µl of PCR product was run on a 1% agarose gel
(Figure 9).
Figure 9. Characterisation of PCR products on a 1% agarose gel.  The coding regions of RT and IN was
amplified by PCR from the plasmid pSVC21 containing the complete HIV-1 HxB2 genome. 1) pGEM standard.
2) and 3) PCR product with RT primers from two identical PCR reactions. 4) and 5) PCR product with IN
primers from two identical PCR reactions.
To estimate the size of the PCR products, the path length of the pGEM standard was
measured and plotted against the number of basepairs (Table 1)
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Table 1. Path length and corresponding size of the pGEM standard
Path length Size (bp)
1 cm 2645
2.1 cm 1605
2.75 cm 1199
4 cm 676
From this a standard curve was drawn and the sizes of the two PCR products estimated
(Figure 10).
The coding region of RT is 1680 basepairs, a size that correspond well with the estimation of
1800 basepairs from the standard curve. For IN the coding region is 891 basepairs, which also
corresponds to the estimation of 825 basepairs.
Figure 10. Standard curve for the estimation of fragment size of PCR products. The path length of the
pGEM standard on an 1% agarose gel was measured and plotted against the size of the bands. From this a
standard curve was drawn. The path length of the two PCR products was measured, and the sizes estimated from
the standard curve.
The RT and IN coding region PCR products were purified to get a high concentration, and cut
with the appropriate restriction enzymes before cloning them into the vector pCITE-5b(+).
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3.1.2 Cloning of RT and IN into the vector pCITE-5b(+)
To be able to clone the amplified coding regions of RT and IN into the vector pCITE-5b(+),
the vector first had to be cut with the appropriate restriction enzymes. Then the cloning was
performed as described in Methods (2.14). Electrocompetent bacteria were transformed with
the cloning products and plasmids were isolated from the positive colonies. 10 µl of an 1:100
dilution of the resulting product was cut with restriction enzymes and run on an 1% agarose
gel as described in Table 2 and Figure 11. The anticipated restriction enzyme digest pattern,
made with the computer program Gene Construction Kit, is also shown.
The plasmid containing the RT gene is called pCITE-RT, and the plasmid containing the IN
gene is called pCITE-IN.
Table 2. Restriction enzyme analysis of pCITE-RT and pCITE-IN
Lane Description
1 pGEM standard
2 Uncut pCITE-RT
3 pCITE-RT cut with BamHI
4 pCITE-RT cut with EcoRI
5 pCITE-RT cut with BamHI and EcoRI
6 Uncut pCITE-IN
7 pCITE-IN cut with BamHI
8 pCITE-IN cut with SacI
9 pCITE-RT cut with BamHI and SacI
10 pGEM standard
Figure 11. Restriction enzyme analysis of pCITE-RT and pCITE-IN. a) The plasmids are cut with restriction
enzymes and run on an 1% agarose gel. 1) pGEM standard. 2) Uncut pCITE-RT. 3) pCITE-RT cut with BamHI.
4) pCITE-RT cut with EcoRI. 5) pCITE-RT cut with both BamHI and EcoRI. 6) Uncut pCITE-IN. 7) pCITE-IN
cut with BamHI. 8) pCITE-IN cut with SacI. 9) pCITE-RT cut with both BamHI and SacI. 10) pGEM standard.
b) Anticipated restriction enzyme digest pattern created with the computer program Gene Construction Kit. The
numbering is the same as in a).
a) b)
Results
39
In lane 2 the strong band corresponds to supercoiled plasmid pCITE-RT. The weaker band
above is open circular plasmid. Lanes 3 and 4 have only linear plasmid as expected. In lane 5
a fragment of approximately 1700 bp is clearly visible. This corresponds to the RT coding
region cut out from the plasmid pCITE-RT. The other band is the linear vector. In lanes 6-9,
the plasmid pCITE-IN is used. This plasmid has a slightly lower concentration, resulting in
weaker bands. In lane 6 the band is supercoiled pCITE-IN. In lanes 7 and 8 the bands
corresponds to linear plasmid. In lane 9 the vector without the IN fragment is visible. The
band corresponding to the IN fragment is hardly visible on the picture (see arrow), but was
visible when the gel was examined under UV-light. This corresponds well with the pattern
obtained when the plasmids were digested using the computer program Gene Construction Kit
(Figure 11b).
These results strongly suggests that the genes HIV-1 RT and IN was successfully inserted into
the vector pCITE-5b(+). The plasmids thus obtained are illustrated in Figure 12.
Figure 12.  The plasmids pCITE-IN and pCITE-RT. he plasmid maps are made using Gene Construction
Kit.
3.1.3 Determination of the concentrations of pCITE-RT and pCITE-IN
The plasmids were purified using a Qiagen Megaprep protocol (see 2.12.3). Th  purified
plasmids were then subjected to a spectrophotometric analysis to determine the concentrations
(Table 3).
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Table 3. Determination of plasmid concentrations
Plasmid Dilution A260 Concentration
pCITE-RT 1:100 0.491 2.5 µg/µl
pCITE-RT 1:1000 0.046 2.3 µg/µl
pCITE-IN 1:100 0.273 1.4 µg/µl
pCITE-IN 1:1000 0.035 1.75 µg/µl
For pCITE-RT the difference in concentration from the two measurements is small, the
conclusion is therefore that the concentration is about 2.4 µg/µl. The difference between the
measurements for pCITE-IN is bigger, but since the A260 value for the 1:1000 dilution is so
low, a concentration of 1.4 µg/µl is believed to be the most correct.
3.1.4 Sequence analysis of recombinant constructs
The plasmids were sequenced using both forward and reverse primers as described in
Methods (2.14.4). 3-400 nucleotides could easily be read for both RT and IN. The
chromatograms obtained was visualised using the computer program Chromas 1.45 (Figure
13). The computer program ClustalX was used to compare the sequences with the published
HIV-1 HxB2 sequence. The only differences found was where an N had been placed in the
sequence. By carefully examine the chromatogram the right nucleotides could be determined.
Only the startpoints and the endpoints of the genes are visualised. The RT gene ends with an
N, but a red peak is clearly visible on the chromatogram. This strongly suggests that the right
nucleotide is a T, which corresponds with the HIV-1 HxB2 sequence.
Figure 13. Chromatograms from the four sequencing reactions.  a) The start- and endpoint of the RT-gene in
the plasmid pCITE-RT is visualised. The restriction enzyme sites are also shown. b) The start- and endpoints of
IN in the plasmid pCITE-IN with restriction enzyme sites. Chromas 1.45 is used to visualise the chromatograms.
a) b)
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3.2 Description of the anticipated proteins
Since both RT and IN are expressed as a polyprotein (Pol) in HIV-1, neither of the proteins
have the start codon needed for translation. These are therefor provided in the vector, yielding
slightly longer polypeptide chains then for the native proteins. RT is in the N-terminal part of
Pol, and thus has no stop-codon either. This is also provided in the vector, giving RT from
pCITE-RT with both an N-terminal and a C-terminal extension. IN has a stop-codon, since IN
is the C-terminal part of Pol.
By using the computer sequence analysis program ClustalX, the anticipated RT and IN
sequences was compared to the HxB2 Pol sequence. The results are shown in Figu 14.
CLUSTAL X (1.64b) multiple sequence alignment
HXB2           ---------------------------------------------PISPIETVPVKLKPG 15
PCITE-RT       MATTHMKETAAAKFERQHMDSPIDGTGSDDDDKSPGFSSTMAISDPISPIETVPVKLKPG 60
                                                            ***************
HXB2           MDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLV 75
PCITE-RT       MDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLV 120
               ************************************************************
HXB2           DFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSI 135
PCITE-RT       DFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSI 180
               ************************************************************
HXB2           NNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEI 195
PCITE-RT       NNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEI 240
               ************************************************************
HXB2           GQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVN 255
PCITE-RT       GQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVN 300
               ************************************************************
HXB2           DIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVIPLTEEAELELAENREILKEPVH 315
PCITE-RT       DIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVIPLTEEAELELAENREILKEPVH 360
               ************************************************************
HXB2           GVYYDPSKDLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQKI 375
PCITE-RT       GVYYDPSKDLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQKI 420
               ************************************************************
HXB2           TTESIVIWGKTPKFKLPIQKETWETWWTEYWQATWIPEWEFVNTPPLVKLWYQLEKEPIV 435
PCITE-RT       TTESIVIWGKTPKFKLPIQKETWETWWTEYWQATWIPEWEFVNTPPLVKLWYQLEKEPIV 480
               ************************************************************
HXB2           GAETFYVDGAANRETKLGKAGYVTNRGRQKVVTLTDTTNQKTELQAIYLALQDSGLEVNI 495
PCITE-RT       GAETFYVDGAANRETKLGKAGYVTNRGRQKVVTLTDTTNQKTELQAIYLALQDSGLEVNI 540
               ************************************************************
HXB2           VTDSQYALGIIQAQPDQSESELVNQIIEQLIKKEKVYLAWVPAHKGIGGNEQVDKLVSAG 555
PCITE-RT       VTDSQYALGIIQAQPDQSESELVNQIIEQLIKKEKVYLAWVPAHKGIGGNEQVDKLVSAG 600
               ************************************************************
HXB2           IRKVL-------------------- 560
PCITE-RT       IRKVLRNSSSVDKLAAALEHHHHHH 625
               *****
a)
Results
42
Figure 14. Sequence alignment. a) Alignment of the HIV-1 HxB2 RT sequence with the anticipated protein
from the pCITE-RT plasmid. b) Alignment of the HIV-1 HxB2 IN sequence with the anticipated protein from
the pCITE-IN plasmid.
This shows that the RT protein translated from the plasmid pCITE-RT will have a 45 aa N-
terminal extension and a 20 aa C-terminal extension. The N-terminal extension contains an S-
tag; which can be utilised to purify the protein. In the C-terminal part, a His-tag has been
added. This tag can also be used as a means to purify the protein. The IN protein produced
from pCITE-IN will only have the N-terminal extension, since it already contains a stop-
codon. This N-terminal extension is the same as for the RT protein.
Since both the proteins produced will have additional amino acids, their molecular
weights will be different from the native viral proteins. To calculate the expected molecular
weights, the ProtParam tool from the ExPASy (Expert Protein Analysis System) proteomics
server of the Swiss Institute of Bioinformatics (SIB) was used.  The results obtained when
using the translated sequences from pCITE-RT and pCITE-IN are given in Table 4.
Table 4. Anticipated molecular weights of RT and IN from pCITE-RT and pCITE-IN.
Native viral proteins pCITE proteins
IN 31 kDa IN 37 kDa
RT (p66) 66 kDa RT (p66) 71.5 kDa
RT (p51) 51 kDa RT (p51) 56 kDa
CLUSTAL X (1.64b) multiple sequence alignment
HxB2            ----------------------------------------------FLDGIDKAQDEHEK 14
pCITE-IN        MATTHMKETAAAKFERQHMDSPIDGTGSDDDDKSPGFSSTMAISDPFLDGIDKAQDEHEK 60
                                                              **************
HxB2            YHSNWRAMASDFNLPPVVAKEIVASCDKCQLKGEAMHGQVDCSPGIWQLDCTHLEGKVIL 74
pCITE-IN        YHSNWRAMASDFNLPPVVAKEIVASCDKCQLKGEAMHGQVDCSPGIWQLDCTHLEGKVIL 120
                ************************************************************
HxB2            VAVHVASGYIEAEVIPAETGQETAYFLLKLAGRWPVKTIHTDNGSNFTGATVRAACWWAG 134
pCITE-IN        VAVHVASGYIEAEVIPAETGQETAYFLLKLAGRWPVKTIHTDNGSNFTGATVRAACWWAG 180
                ************************************************************
HxB2            IKQEFGIPYNPQSQGVVESMNKELKKIIGQVRDQAEHLKTAVQMAVFIHNFKRKGGIGGY 194
pCITE-IN        IKQEFGIPYNPQSQGVVESMNKELKKIIGQVRDQAEHLKTAVQMAVFIHNFKRKGGIGGY 240
                ************************************************************
HxB2            SAGERIVDIIATDIQTKELQKQITKIQNFRVYYRDSRNPLWKGPAKLLWKGEGAVVIQDN 254
pCITE-IN        SAGERIVDIIATDIQTKELQKQITKIQNFRVYYRDSRNPLWKGPAKLLWKGEGAVVIQDN 300
                ************************************************************
HxB2            SDIKVVPRRKAKIIRDYGKQMAGDDCVASRQDED 288
pCITE-IN        SDIKVVPRRKAKIIRDYGKQMAGDDCVASRQDED 334
                **********************************
b)
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These results are important for the interpretation of results from i. e. Western blots, where the
bands will appear higher up on the blot than expected from molecular weights of the native
proteins.
3.3 In vitro transcription and translation
3.3.1 Production of protein batches
The proteins produced by in vitro transcription and translation was to be used in a protein-
protein interaction study with ELISA. For this purpose, 50 µl of protein from one in vit
transcription and translation reaction was not enough. Therefore nine parallel reactions were
set up for both RT and IN. The procedure was followed as described in Methods (2.15.1).
After the incubation, a total amount of 50 µl of reticulocyte lysat containing either RT or IN
was obtained from each reaction. The concentration of RT and IN in solution was not
determined at this point.
Figure 15.  In vitro translated HIV-1 RT and IN. a) 5 µl of 9 parallel in vitro transcription and translation
reactions with pCITE-IN was run on a 10 % SDS-acrylamide gel and blotted onto a nitrocellulose membrane. IN
was visualised using the IN-antibodies 8G4 and 8E5 [84], anti-mouse-POD as secondary antibody and detected
by ECL. b ) 5 µl of 9 parallel in vitro transcription and translation reactions with pCITE-RT was run on a 10 %
acrylamide gel and blotted onto a nitrocellulose membrane. RT was visualised using the RT-antibodies 8C4 and
11B7 [83], anti-mouse-POD as secondary antibody and detected by ECL.
a)
b)
RT
IN
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Following, 5 µl from each reaction was run on an 10 % acrylamide gel and visualised
by Western blotting using a mix of three different monoclonal antibodies for each protein
(Figure 15).
In Figure 15a, the nine parallel in vitro translation reactions producing IN are shown.
A strong band above 32.5 kDa is clearly visible for all nine reactions. This is in good
accordance to the results obtained using the ProtParam tool from the ExPASy proteomics
server of SIB (see Table 4). The results therefor strongly suggest that IN has been produced.
There are in addition several other bands visible. There are two strong bands at approximately
47.5 kDa and a weaker band below 30 kDa. Possible explanations for these bands are given in
Discussion (4.2.2). In Figure 15b, the nine in vitro translation reactions for RT are shown. On
this blot, a band between 62 and 83 kDa is visible. Also this is in good accordance to the
results obtained using the ProtParam tool from the ExPASy proteomics server of SIB (see
Table 4) suggesting that RT as well has been succesfully produced. A strong lower band is
visible on this blot, in addition to several other weaker bands. See Discussion (4.2.2) for
further details.
The reason for the difference in intensity of the RT and IN bands need not be a
difference in concentration. The intensity of bands with the same concentration varies from
time to time when ECL is used, due to the high sensitivity of this system.
After the verification of the protein products, the nine in vitro translation reactions for
each protein were pooled, giving a batch of protein to use in the ELISA-experiments. Before
the ELISA-experiments can be carried out, it is thus important that the protein concentrations
are determined.
3.3.2 Determination of protein concentrations
Before assaying for RT-IN interactions, an approximately protein concentration must be
decided. Since the proteins produced are in a reticulocyte lysate containing many other
proteins, regular protein concentration assays can not be utilised. The protein concentrations
are therefore approximated on Western blots. 5 µl of the lysates containing either IN or RT
was run on an acrylamide gel together with from 0.1 to 1 µg of purified IN or RT. The results
are shown in Figure 16.
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Figure 16. Determination of protein concentrations. a) The samples were run on a 10% SDS-acrylamide gel
and blotted onto a nitrocellulose membrane. 1) 15 µl Broad-Range protein standard. 2) 5 µl of the IN pool. 3) 1
µg of purified IN. 4) 0.5 µg of purified IN. 5) 0.2 µg of purified IN. 6) 0.1 µg of purified IN. b) The samples
were run on a 10% acrylamide gel and blotted onto a nitrocellulose membrane.1) 15 µl Broad-Range protein
standard. 2) 5 µl of the RT pool. 3) 1 µg of purified RT. 4) 0.5 µg of purified RT. 5) 0.2 µg of purified RT. 6) 0.1
µg of purified RT.
The band for the in vitro translated IN is quite strong. For the purified IN, only the
bands corresponding to 5 and 2.5 µg of IN are visible on the blot. The band in lane 2 is
weaker than these bands, giving a concentration of between 0.5 and 0.2 µg of IN in the 5 µl
sample. This is only an approximation, since it is difficult to determine protein concentrations
on Western blots. For RT the situation is different. Here, the band for the in vitro translated
RT is quite weak, while all the bands for the purified RT are all strong. This means that the
amount of in vitro translated RT on the blot are less then 0.1 µg from the 5 µl sample.
The concentrations found differ slightly for the two proteins. This can be associated
with the difference in size for RT and IN. Nevertheless, the amounts of protein produced
should be sufficient for protein-protein interaction studies to be carried out.
3.4 Results with ELISA
In order to detect any physical interactions between RT and IN, a direct ELISA was
performed (see 2.17). A standard curve for each protein was first determined, using purified
proteins. The results are shown in Table 5 and Figure 17.
Table 5. Standard curves for RT and IN
RT concentrationAbsorbance at 492 nmIN concentrationAbsorbance at 492 nm
10 µg 2.239 10 µg 2.059
5 µg 2.056 5 µg 1.991
2.5 µg 2.071 2.5 µg 1.892
1.25 µg 1.905 1.25 µg 1.512
0.625 µg 1.431 0.625 µg 0.824
a) b)IN RT
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Figure 17. Standard curves for RT and IN. Increasing amounts of purified RT or IN was added to each well,
and the procedure followed as described in 2.17
The curves show a saturation of proteins in some of the wells. It is obvious that 10 µg of
protein is too much, it seems that also 5 µg is on the upper edge. When the two highest
protein concentrations are removed, the standard curves become almost linear (see Figure 18).
Figure 18. Revised standard curves for RT and IN. The wells where a too high amount of protein was added
have been omitted in order to get linear standard curves.
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Two different formats of the direct ELISA were performed. In the first format,
decreasing amounts of in vitro translated IN was added to the wells. Following incubation and
blocking, a fixed amount of in vitro translated RT was added to all the wells containing IN. A
well incubated with the negative control lysate was also added RT. The rest of the procedure
was followed as described in 2.17. The second format was performed exactly as the first, only
that the first incubation was with RT and the second with IN. The results are shown in Table
6.
Table 6. Results from the ELISA experiments.
Amount of putative
interacting proteins addedAbs. 492 nm
Amount of putative
interacting proteins addedAbs. 492 nm
50 µl 1:2 IN from pCITE-IN +
50 µl 1:2 RT from pCITE-RT 0.628
50 µl 1:2 RT from pCITE-RT +
50 µl 1:2 IN from pCITE-IN 1.994
50 µl 1:4 IN from pCITE-IN +
50 µl 1:2 RT from pCITE-RT 0.642
50 µl 1:4 RT from pCITE-RT +
50 µl 1:2 IN from pCITE-IN 1.939
50 µl 1:8 IN from pCITE-IN +
50 µl 1:2 RT from pCITE-RT 0.664
50 µl 1:8 RT from pCITE-RT +
50 µl 1:2 IN from pCITE-IN 1.962
50 µl 1:16 IN from pCITE-IN +
50 µl 1:2 RT from pCITE-RT 0.626
50 µl 1:16 RT from pCITE-RT +
50 µl 1:2 IN from pCITE-IN 1.975
50 µl 1:32 IN from pCITE-IN +
50 µl 1:2 RT from pCITE-RT 0.583
50 µl 1:32 RT from pCITE-RT +
50 µl 1:2 IN from pCITE-IN 2.056
50 µl 1:2 Negative control +
50 µl 1:2 RT from pCITE-RT 0.665
50 µl 1:2 Negative control +
50 µl 1:2 IN from pCITE-IN 2.005
As seen in Table 6, the results for both the experiments are the same for all the dilutions and
also for the negative controls. This means that the proteins added in the second coating have
bound equally to all the wells, regardless of the amount or identity of the proteins added in the
first coating. An other conclusion that can be drawn, is that the concentration of the in vitro
translated IN is much higher than the in vitro translated RT. This corresponds well with the
results obtained in 3.3.2. From the standard curve (Figure 18), the amount of RT in 50 µl of
lysate is less than 0.625 µg. The corresponding amount of IN is between 2.5 and 10 µg. It is
impossible to determine this exactly, because of the saturation of protein in the standard curve
for IN.
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4 Discussion
The HIV-1 proteins reverse transcriptase and integrase have been produced by in vitro
transcription and translation. The proteins produced have higher molecular weights than the
native viral proteins. An ELISA-format has been employed in order to detect possible direct
interactions between the synthesised proteins. A protein-protein interaction could not be
detected by this method. A number of different parameters could have caused the detection of
RT-IN interactions to fail. These parameters need to be changed in future experiments.
4.1 Construction and verification of plasmids containing RT and IN
DNA encoding reverse transcriptase and integrase from the HIV-1 were amplified from a
plasmid containing the full-length HxB2 sequence by PCR. This produced fragments with
sizes corresponding to the coding regions of both RT and IN as verified by agarose gel
electrophoresis. The DNA was purified, cut with restriction enzymes and cloned into the in
vitro translation vector pCITE-5b(+).
4.1.1 The vector pCITE-5b(+)
This vector was chosen because it is d signed for increased translational performance of RNA
prepared from cloned DNA sequences. The plasmid carry a segment of the
encephalomyocarditis virus (EMCV) RNA 5' non-coding region, that functions as an internal
entry point for initiation of translation by mammalian ribosomes. This Cap-Independent
Translation Enhancer (CITE) should dramatically increase the in vitro translation efficiency
of synthetic RNA by rabbit reticulocyte lysates. Since this was the only vector used, it is
difficult to say if this vector really gave the best efficiency of translation.
4.1.2 Cloning and sequencing
The cloning was performed directly in low melting-point agarose in order to avoid the extra
purification step. The cloning efficiency was high, indicating that the cloning-procedure is
efficient as well as being easy to perform. After the cloning, the plasmids were subjected to
restriction enzyme analysis in order to verify that RT and IN was inserted into the vector. The
results of this analysis confirmed that the right genes were inserted. The sequences of the
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plasmids obtained were then determined. This confirmed that the genes were inserted in the
right reading frame.
4.1.3 Anticipated proteins
Both RT and IN are enzymatically cleaved from the viral polyprotein Pol when HIV-1 infects
host cells. For RT a homodimer of p66 is formed before PR cleaves one of the monomers
giving the p66/p51 heterodimer. IN is cleaved from the C-terminal part of Pol giving a protein
of 31 kDa. When RT is going to be in vitro translated, both start- and stop-codons need to be
introduced from the vector sequence. The in vitro translation vector pCITE-5b(+) has start-
codons and stop-codons flanking the multiple cloning-site in all three reading-frames. Since
the RT-gene was cloned into pCITE-5b(+) in the correct reading frame, the start- and stop-
codons were introduced. After the start-codon in pCITE-5b(+), an S-tag is present. This will
facilitate an eventual purification of the protein using an affinity column. In the C-terminal
part, a His-tag is added before the stop-codon. This can also be used as a means to purify the
protein. IN is the C-terminal part of Pol, and thus has a stop-codon. The C-terminal His-tag is
therefor not introduced here. Only the N-terminal S-tag is added, as for the RT protein.
When these extra amino acids are added to the proteins, their molecular weights
change (3.2). This can affect their ability to interact. Additional amino acids can dramatically
change the folding of a protein, giving a different 3-dimentional structure. Protein-protein
interactions are dependent on tertiary structure, and the effects of the additional amino acids
in the in vitro translated proteins are not known. An easy way to check if the structure is
affected, is by using activity assays for both the proteins. If the proteins are active, their
folding is most likely correct and a possible interaction would not be affected. This however,
requires purified proteins and was not done in this project.
4.2 In vitro transcription and translation
The in vitro transcription and translation was performed using the TNT® Quick Coupled
Transcription/Translation Systems from Promega. The incubation time was varied from 0.5 to
1.5 hours without detecting any difference neither in the amount nor quality of the protein
produced. This is the time the manufacturer recommends for optimal in vit otranscription and
translation.
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4.2.1 Labelling of proteins
At first the proteins were labelled with biotin by the way of biotin-lysyl-tRNAs (Figure 19).
This enabled an easy detection on Western blots using streptavidin. However, the effect of
biotin on the putative protein-protein interactions between RT and IN is uncertain. Since 9.9%
of the residues in RT produced from pCITE-RT are lysines and the corresponding number for
IN is 8.4%, a substantial part of the protein would be marked. Lysine residues are usually
exposed at the aqueous-facing exterior of the protein. The presence of biotinylated lysines
may or may not affect the function of the modified protein. For example, the enzymatic
activity of ß-galactosidase is reduced by the incorporation of biotinylated lysines but
luciferase and chloramphenicol acetyltransferase (CAT) are affected less [86]. Since the
effects on RT and IN are unknown, it was decided to synthesise the proteins unmarked.
Figure 19. Structure of Transcend™ tRNA. The Transcend™ tRNA is a biotinylated lysyl-tRNA, where the
biotin moiety is linked to lysine by a spacer arm. The figure is adapted from Promegas Technical Bulletin No.
182, page 2.
The unmarked proteins were analysed by SDS-PAGE. Several attempts were done to
visualise the proteins by Coomasssie-staining. This was never successful; the only bands
appearing were the lysate proteins as compared to the negative controls. Since nothing
appeared to be on the gel, the procedure for in vitro t anscription and translation was
questioned. Several adjustments of time and temerature of incubation were made, but nothing
did appear on the gel when using the Coomassie-staining. Since adjusting the procedure did
not yield any changes, an explanation for the missing proteins could be that the concentrations
were two low to be detected by Coomassie-staining. To verify this, Western blotting was
performed. When using a mix of three different monoclonal antibodies for each protein, bands
at the appropriate sizes were present after developing the radiography film. Western blotting
is a more sensitive method than Coomassie-staining, and lower protein concentrations can be
detected. From 30 to 100 ng of protein per band is detectable by Coomassie staining methods
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[87]. With the ECL Western blotting detection reagents, less then 1 pg of protein can be
detected.
4.2.2 Production of proteins
At first, nine parallel in vitro translation reactions were performed for RT and IN. This was
done in order to get a batch of protein that could be used in later ELISA experiments. The
resulting proteins were visualised by Western blotting. Bands at the right molecular weights
appeared on the blots after developing with ECL (Figure 15). There were also several
additional bands. For IN two bands at approximately 47.5 kDa were visible. These bands are
too low to be a dimer of IN. A possible explanation is that the bands represent different forms
of degraded dimer. There are also several lower bands, which also can represent degradation
products of IN. Two different monoclonal antibodies recognising different epitopes of IN
were utilised for detection on Western blots. These antibodies show no detectable cross-
reactivity with bacterial proteins [84]. It is not known whether there exists cross-reactivity
between the antibodies used and proteins in the reticulocyte lysate. For RT, the additional
bands were lower than the band corresponding to the produced RT. These bands can
correspond to p66 and p51 without one or both of the tags added from the vector. If  the RT
produced folds correctly, the tags will most likely protrude from the structure and be
accessible for proteolytic attacks. An other explanation for the extra bands is that RT is
degraded. The antibodies utilised for detection recognises the same epitope on both p66 and
p51. These antibodies are not known to cross-react.
The sensitivity of the ECL system is also very high. Small differences in the time of exposure
to the radiography film gave big differences in the appearance of the blot. The first bands
appearing on the film were still always the bands corresponding to RT and IN.
These nine in vitro translation reactions were pooled and a sample from the pool was
blotted together with purified RT and IN respectively. This was done in order to get an
impression of the concentration of proteins of interest in the pool. For RT a concentration of
less than 20 ng/µl was found. The corresponding concentration of IN is between 40 and 100
ng/µl. These concentrations are higher than what could be expected. Promega states that
although expression levels for different genetic constructs can vary greatly due to many
factors, most gene constructs will generate 50-300 ng of protein in a standard 50 ml reaction in
one hour. The high yield of protein using the vectors pCITE-RT and pCITE-IN is probably
due to the CITE-sequence in the vector.
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4.3 ELISA
4.3.1 Direct ELISA
A direct ELISA-format was employed in order to detect possible protein-protein interactions
between in vitro translated HIV-1 RT and IN. This format is previously successfully utilised
to detect interactions between HIV-1 Nef and the two proteins Lck and MAPK (Mitogen-
activated protein kinase) by using purified proteins [85]. In this thesis reticulocyte lysates
containing the putative interacting proteins were employed in the ELISA. This resulted in the
same results for both the dilution series and the negative control (3.4). One reason for this can
be that the blocking was incomplete, but the absorbance for the wells that were only added
PBS is so low that this explanation is unlikely. An other explanation can be that there are
some endogenous proteins in the reticulocyte lysate that are interacting with RT and IN. This
would explain the results for the negative controls. Considering the dilution series, a possible
explanation for the identical results for all dilutions could be that the amount of endogenous
proteins in the reticulocyte lysate is so high that even a 1:32 dilution is enough to get a
saturation of proteins in the wells. Is seems therefor that this ELISA format has to be used
with purified proteins in order to avoid unspecific binding.
From the results obtained with ELISA, the concentrations of produced proteins can be
verified. From the standard curves a concentration of less that 25 ng/µl is de ermined for RT.
The concentration of IN is more difficult to determine, because the absorbance is at the
saturation level. A concentration of less than 100 ng/µl is the most accurate result possible.
These concentrations correspond well to those found by Western blotting.
4.3.2 Other ELISA formats
If the reticulocyte lysate is going to be used with ELISA, an indirect ELISA might be better.
In an indirect ELISA, the wells are coated with an antibody, not an antigen. Then only the
protein of interest will bind to the wells. For the coating with the putative interacting protein
however, the lysate has to be used. It is therefore not certain that performing an indirect
ELISA will rule out the problem of unspecific binding.
If ELISA is going to be used to detect protein-protein interactions between two in vi ro
translated protein; the proteins should first be purified. This should be done to avoid any non-
specific binding between the proteins of interest and the proteins in the reticulocyte lysate.
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The concentration of protein would also be higher if the proteins are purified from the
reticulocyte lysate.
4.4 RT-IN interactions
It is not evident that direct physical interactions between RT and IN should be present. The
PIC consists of several other proteins, both viral and cellular. In addition; both viral RNA and
DNA are associated. An interaction between RT and IN may require several other factors
linking the two proteins together. Two different methods have previously been used in the
search for RT-IN interactions; the yeast two-hybrid system and an in vitro binding assay.
When the yeast two-hybrid system was applied, no interactions or even hybrid proteins could
be detected [82]. The plasmids were successfully rescued from the yeast-cells after
transformation, but the two hybrid proteins were undetectable. The most likely explanation
for this was that the expression level of proteins was too low. Several factors need to be
adjusted if the yeast two-hybrid system is going to be utilised to detect RT-IN interactions.
When an in vitro binding assay was applied [75], a GST-IN fusion protein was shown to
efficiently pull down a RT heterodimer protein from crude bacterial lysates. Empty G-beads
or GST protein-bound G-beads were not able to pull down RT, indicating the specificity of
the RT-IN interaction. The RT-IN reaction mixture was pretreated with micrococcal nuclease
to rule out the possibility that nucleic acids facilitated the association of RT and IN. This
treatment did not decrease the amount of RT pulled down.
It is impossible to conclude if the RT-IN interaction really exists on the basis of only these
two publications. With the yeast two-hybrid system no interactions could be detected due to
low expression of proteins. With the in vitro binding assay, interactions were detected
between the two proteins. This was however only done in vitro, so how this will be in vivo is
not yet determined.
4.5 Conclusions
The two in vitro translation vectors containing HIV-1 RT and IN seemed to function
satisfying. Since the plasmids contained the CITE-sequence, the efficiency of translation was
high. The two proteins were not purified, in order to check if interactions between them could
be detected without this step. This was not successful, at least not with the ELISA format
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utilised in this project. A high degree of unspecific binding was found and a conclusion of
interactions could not be drawn.
4.6 Future strategies
The main purpose of identifying RT-IN interactions is to better understand the organisation of
the PIC. There are numerous methods to study such interactions; ELISA is only one of them.
If in vitro translated proteins shall be used to study such interactions; the proteins should
either be purified or cotranslated. Cotranslation of RT, IN and others of the PIC-members
could give interesting answers.
The dynamics of the PIC can also be studied with the Biacore system. This system enables
investigations of macromolecular organisations and transient interactions. Further
developments of the yeast two-hybrid system are also a good means of studying the PIC.
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